<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871308</url>
  </required_header>
  <id_info>
    <org_study_id>2104-072-1212</org_study_id>
    <nct_id>NCT04871308</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Myocardial Protection</brief_title>
  <acronym>DEXCARD</acronym>
  <official_title>Cardioprotective Effect of Dexmedetomidine in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: a Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine, an alpha-2 agonist, is a sedative that is widely used in various clinical&#xD;
      settings because, compared to benzodiazepines, it preserves respiratory function better and&#xD;
      its duration of action is short.&#xD;
&#xD;
      Recent experimental studies showed a possibility that dexmedetomidine may have an&#xD;
      organoprotective effect from ischemic-reperfusion injury by reducing inflammatory response.&#xD;
      Besides, dexmedetomidine is known to be related with attenuated sympathetic tone and improved&#xD;
      microcirculation.&#xD;
&#xD;
      Taken together, it is plausible that dexmedetomidine exerts cardioprotection in patients&#xD;
      undergoing cardiac surgery with cardiopulmonary bypass and aortic cross-clamp.&#xD;
&#xD;
      The aim of this trial is to test the effect of dexmedetomidine on postoperative cardiac&#xD;
      troponin I measurements in patients undergoing cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac troponin I</measure>
    <time_frame>Three days after surgery</time_frame>
    <description>Area under the curve of cardiac troponin I measured at 0, 6, 24, 48, 72 hours after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group using normal saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.&#xD;
From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  cardiac surgery utilizing cardiopulmonary bypass and aortic cross-clamp&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coronary artery bypass grafting&#xD;
&#xD;
          -  Concomitant cryo-Maze procedure&#xD;
&#xD;
          -  Myectomy&#xD;
&#xD;
          -  Heart transplantation&#xD;
&#xD;
          -  Concomitant major non-cardiac surgery&#xD;
&#xD;
          -  Isolated complicated congenital heart surgery&#xD;
&#xD;
          -  descending thoracic aorta surgery with partial cardiopulmonary bypass&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Minimally invasive or robot-assisted surgery&#xD;
&#xD;
          -  Estimated GFR &lt;30 ml/min/1.73 m2&#xD;
&#xD;
          -  Documented end-stage renal disease&#xD;
&#xD;
          -  Preoperative renal replacement therapy&#xD;
&#xD;
          -  Preoperative history of percutaneous coronary intervention within 6 month before&#xD;
             surgery&#xD;
&#xD;
          -  Acute coronary syndrome within 4 weeks before surgery&#xD;
&#xD;
          -  Preoperative mechanical circulatory support devices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karam Nam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karam Nam, M.D.</last_name>
    <phone>+82 2 2072 3108</phone>
    <email>karamnam@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karam Nam, M.D.</last_name>
      <phone>+82 2 2072 3108</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Karam Nam, MD</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

